

DATE:	11 December 2023
TO:	All Zones – Physicians, Nurses, Pharmacists, and Managers
FROM:	Clinical Biochemistry, Alberta Precision Labs (APL)
RE:	Optimization of Infliximab Order and Infliximab Total Antibodies Reporting

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective **December 11, 2023**, changes to *Infliximab* order and *Infliximab Total Antibodies* reporting will go live in Connect Care.

Background

- Current workflows for ordering *Infliximab* in Connect Care and via the Infliximab Level Order Form are time-consuming for the ordering provider and the laboratory.
- Incomplete orders contribute to delays in *Infliximab* and *Infliximab Total Antibodies* result reporting.

How this will impact you

- Following provincial consultation with pediatric and adult gastroenterology, the following *Infliximab* order questions will be removed from Connect Care and the Infliximab Level Order Form:
 - ✓ Drug formulation
 - ✓ Dose and dose frequency
 - ✓ Date of last infusion
 - ✓ Patient weight at time of collection
- New *Infliximab Total Antibodies* reporting comments are shown below:

Value (AU/mL)	New Report Comments	Change
<25	Undetectable antibodies to infliximab	Removed dose optimize.
25 - 275	Detectable antibodies to infliximab.	Removed dose optimize.
276 - 492	Detectable antibodies to infliximab.	Removed consider therapy change.

Action Required

- Continue to provide clinical indication to ensure the proper therapeutic range is applied to the report.
- Inform the lab when new biosimilar formulations become available in Alberta for IBD patients.
- Refer to the updated Infliximab Level Order Form on the Alberta Health Services website.
- Be aware of *Infliximab* order and *Infliximab Total Antibodies* reporting changes.
- For urgent requests or to add on *Infliximab Total Antibodies*, contact the on-call clinical biochemist.



Questions/Concerns

- Kareena Schnabl, Clinical Biochemist: 780 407-3186; kareena.schnabl@aplabs.ca

Approved by

- Dr. Allison Venner, Associate Section Chief, Clinical Biochemistry, APL
- Dr. Michael Mengel, Medical Director, North Sector, APL
- Dr. Paul Klonowski, Associate Medical Director, South Sector, APL

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.